Genmab A/S SEC filings GNMSF
Genmab A/S has 566 filings in SEC EDGAR's recent list, going back to Apr 28, 2008. Its latest annual report, Form 20-F, was filed on Feb 17, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Nov 5, 2026.
| Form | Description | Filed | Period |
|---|---|---|---|
| SC TO-T/A | Filing | Dec 30, 2025 | — |
| SC TO-T/A | Filing | Dec 12, 2025 | — |
| SC TO-T/A | Filing | Dec 9, 2025 | — |
| SC TO-T/A | Filing | Oct 31, 2025 | — |
| SC TO-T | Filing | Oct 21, 2025 | — |
| SC TO-C | Tender offer statement | Sep 29, 2025 | — |
| EFFECT | Filing | Jul 15, 2025 | — |
| EFFECT | Filing | Jul 17, 2019 | — |
| CERT | Filing | Jul 15, 2019 | — |
| 8-A12B | Filing | Jul 12, 2019 | — |
| CORRESP | Letter to the SEC | Jul 12, 2019 | — |
| CORRESP | Letter to the SEC | Jul 12, 2019 | — |
| SEC STAFF LETTER | Filing | Jun 14, 2019 | — |
| CORRESP | Letter to the SEC | May 28, 2019 | — |
| UPLOAD | Letter from the SEC | May 15, 2019 | — |
| DRSLTR | Filing | May 13, 2019 | — |
| DRS/A | Filing | May 13, 2019 | — |
| SEC STAFF LETTER | Filing | Apr 12, 2019 | — |
| UPLOAD | Letter from the SEC | Apr 11, 2019 | — |
| DRSLTR | Filing | Apr 2, 2019 | — |
| DRS/A | Filing | Apr 2, 2019 | — |
| UPLOAD | Letter from the SEC | Feb 28, 2019 | — |
| DRS | Filing | Feb 5, 2019 | — |
| EFFECT | Filing | May 29, 2013 | — |
| SUPPL | Auto-generated paper document | Apr 28, 2008 | — |
| 12G3-2B | Auto-generated paper document | Apr 28, 2008 | — |
Showing 26 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GMAB (Nasdaq), GNMSF (OTC)
- Headquarters
- 1253 Copenhagen K, Denmark
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1434265
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.